EF Hutton Maintains Buy on VolitionRX, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for VolitionRX (AMEX:VNRX) and maintained a price target of $5.
November 01, 2024 | 11:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for VolitionRX and maintained a price target of $5, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $5 price target by EF Hutton suggests a positive outlook for VolitionRX, likely boosting investor confidence and potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100